Alzamend Neuro, Inc. (ALZN) - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on September 29, 2023, by Alzamend Neuro, Inc., a Delaware corporation trading on The Nasdaq Capital Market. The report addresses two primary events: a notice of non-compliance with Nasdaq listing standards regarding Market Value of Listed Securities (MVLS) and the results of a Special Meeting of Stockholders held on the same date.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Corporate Actions
- Nasdaq Listing Notice: On September 26, 2023, the Company received notice from Nasdaq that its MVLS had been below the $35 million minimum requirement for 30 consecutive business days.
- Compliance Period: The Company has 180 calendar days (until March 25, 2024) to regain compliance. To do so, the MVLS must close at $35 million or more for 10 consecutive business days.
- Delisting Risk: Failure to regain compliance by the deadline may result in delisting from the Nasdaq Capital Market, subject to appeal rights.
- Stockholder Vote: Stockholders approved a proposal to amend the Certificate of Incorporation to authorize a reverse stock split.
- Reverse Split Parameters: The Board may effect a reverse split at a ratio between 1-for-2 and 1-for-20 at any time prior to September 28, 2024.
Voting Results
| Vote Category | Number of Votes |
|---|---|
| For | 58,463,491 |
| Against | 9,749,936 |
| Abstain | 44,645 |
| Broker Non-Votes | 1,609,492 |
Outlook, Risks, and Contingencies
The primary risk identified is the potential delisting of the Company's common stock if the MVLS requirement is not met by March 25, 2024. The Company intends to utilize the approved reverse stock split authority to potentially increase the share price and meet the MVLS threshold. There are no immediate impacts on trading, as the stock remains listed pending the outcome of the compliance period.
Investor Verification Checklist
- Verify the current Market Value of Listed Securities (MVLS) to assess proximity to the $35 million threshold.
- Monitor Board announcements regarding the specific reverse stock split ratio and implementation date.
- Review the definitive proxy statement (Schedule 14A) filed on August 24, 2023, for detailed rationale on the reverse split.
- Track the 180-day compliance window ending March 25, 2024, for potential delisting notices.